CL2023001388A1 - Treatment or prevention of HIV infection. - Google Patents

Treatment or prevention of HIV infection.

Info

Publication number
CL2023001388A1
CL2023001388A1 CL2023001388A CL2023001388A CL2023001388A1 CL 2023001388 A1 CL2023001388 A1 CL 2023001388A1 CL 2023001388 A CL2023001388 A CL 2023001388A CL 2023001388 A CL2023001388 A CL 2023001388A CL 2023001388 A1 CL2023001388 A1 CL 2023001388A1
Authority
CL
Chile
Prior art keywords
prevention
treatment
hiv infection
rilpivirine
microparticles
Prior art date
Application number
CL2023001388A
Other languages
Spanish (es)
Inventor
Steven M Vesole
Guenter Karl Wilhelm Kraus
Herta Maria Ludovica Crauwels
René Holm
Nico Rudolph Niemeijer
Iwan Caroline F Vervoort
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of CL2023001388A1 publication Critical patent/CL2023001388A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01063—1,2-Alpha-L-fucosidase (3.2.1.63)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con el tratamiento o la prevención de la infección por VIH mediante el uso de rilpivirina o una sal farmacéuticamente aceptable de esta en forma de micropartículas o nanopartículas en suspensión en combinación con una hialuronidasa. La presente invención también se relaciona con la rilpivirina o una sal farmacéuticamente aceptable de esta en forma de micropartículas o nanopartículas en suspensión.The present invention relates to the treatment or prevention of HIV infection by the use of rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in suspension in combination with a hyaluronidase. The present invention also relates to rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in suspension.

CL2023001388A 2020-11-17 2023-05-15 Treatment or prevention of HIV infection. CL2023001388A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063114997P 2020-11-17 2020-11-17

Publications (1)

Publication Number Publication Date
CL2023001388A1 true CL2023001388A1 (en) 2023-11-03

Family

ID=78916552

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001388A CL2023001388A1 (en) 2020-11-17 2023-05-15 Treatment or prevention of HIV infection.

Country Status (4)

Country Link
CL (1) CL2023001388A1 (en)
TW (1) TW202233192A (en)
UY (1) UY39520A (en)
WO (1) WO2022109555A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202406551A (en) 2022-04-22 2024-02-16 愛爾蘭商健生科學愛爾蘭無限公司 Freeze dried compositions
WO2023203258A1 (en) 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Liquid compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (en) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidines derivatives
DE602004024041D1 (en) 2003-03-05 2009-12-24 Halozyme Inc SOLUBLE HYALURONIDASE GLYCOPROTEIN (SHASEGP), METHOD OF ITS PREPARATION, USES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF
CA2654115C (en) 2006-06-23 2015-12-22 Tibotec Pharmaceuticals Ltd. Aqueous suspensions of tmc278

Also Published As

Publication number Publication date
WO2022109555A1 (en) 2022-05-27
TW202233192A (en) 2022-09-01
UY39520A (en) 2022-05-31

Similar Documents

Publication Publication Date Title
CL2023001388A1 (en) Treatment or prevention of HIV infection.
DOP2021000147A (en) THERAPEUTIC COMBINATION COMPRISING LAMIVUDINE
UY30431A1 (en) TMC278 WATERPROOF SUSPENSIONS
DOP2016000265A (en) 4' SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
AR099632A1 (en) TREATMENT OF A VIRAL INFECTION OF HEPATITIS C, THAT USES A COMBINATION OF COMPOUNDS
IN2013MU01749A (en)
CO2020000328A2 (en) Long-term formulations
CL2020000860A1 (en) Chroman monobactam compounds for the treatment of bacterial infections.
DOP2018000183A (en) USEFUL COMPOUND FOR THE TREATMENT AND PROPHYLAXIS OF HIV AND AIDS AND ITS USES
CL2017000714A1 (en) Long-acting pharmaceutical compositions
SV2017005418A (en) AURORA CINASA INHIBITOR A
CO2023001340A2 (en) long term formulations
PE20170523A1 (en) TABLET FORMULATION OF 2-FLUOR-N-METHYL-4- [7- (QUINOLIN-6-YLMETHYL) IMIDAZO [1,2- B] [1,2,4] TRIAZIN-2-IL] BENZAMIDE
CO2017008550A2 (en) Antibacterial composition of silver nanoparticles attached to a dispersing agent
AR084487A1 (en) PROSTESIC COMPONENT WITH A SLIDING SURFACE CONTAINING AN ANTIMICROBIAL COATING
MX2019004767A (en) Dispersible compositions.
MA40805A (en) LONG-ACTION PHARMACEUTICAL COMPOSITIONS AGAINST HEPATITIS C
MX2023005758A (en) Treatment or prevention of hiv infection.
BR112017022864A2 (en) antibacterial compositions
MX2022001266A (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases.
BR112017022870A2 (en) antibacterial compositions
MX2023005760A (en) Treatment or prevention of a disease or disorder.
IT201700093527A1 (en) Composition based on strains of bacteria and / or their derivatives for stimulation of the immune system topically or systemically for the treatment of viral infections such as Papilloma virus
MX2022001271A (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases.
AR109364A1 (en) ANTIVIRAL COMPOUNDS